Aslani, Nikka M.

HRN: 21-81-63  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/15/2022
AMPICILLIN 1GM (VIAL)
08/15/2022
08/22/2022
IV
150mg
Q6hours
PCAP-C
Waiting Final Action 
08/15/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/15/2022
08/22/2022
IV
30mg
Q8hours
PCAP-C
Waiting Final Action 
11/20/2022
CEFUROXIME 750MG (VIAL)
11/20/2022
11/27/2022
IV
375mg
Q8
Pneumonia
Waiting Final Action 
01/25/2025
CEFTRIAXONE 1G (VIAL)
01/24/2025
01/31/2025
IV
340mg
Q12h
UTI
Waiting Final Action 
05/30/2025
CEFUROXIME 750MG (VIAL)
05/30/2025
06/06/2025
IV
360mg
Q8H
PCAP C
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: